Stocks · News reference

Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis

Jul 30, 2026, 8:19 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 23, 2026, 6:06 PMVandana Singh
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Read original at benzinga
ABVX AMGN JNJ MRK PALI
BenzingaJul 17, 2026, 6:04 PMBenzinga Newsdesk
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra
Read original at benzinga
ABVX AZN LLY
BenzingaJul 9, 2026, 3:59 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175
Read original at benzinga
ABVX
BenzingaJul 1, 2026, 12:40 PMBenzinga Newsdesk
Abivax Announces Pricing Of Underwritten Public Offering Of 6.40M ADSs At $125.00 Each
Read original at benzinga
ABVX PARIS:FR
BenzingaJun 1, 2026, 8:08 PMBenzinga Newsdesk
Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary
Read original at benzinga
ABVX PARIS:FR